A Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of JNJ-77474462 in Healthy Participants
Latest Information Update: 12 Jul 2021
At a glance
- Drugs Bermekimab (Primary) ; Bermekimab (Primary) ; Anakinra
- Indications Atopic dermatitis; Hidradenitis suppurativa; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 05 Jul 2021 Status changed from recruiting to completed.
- 10 May 2021 Planned End Date changed from 10 May 2021 to 26 May 2021.
- 10 May 2021 Planned primary completion date changed from 29 Apr 2021 to 26 May 2021.